Adjuvant interleukin-2, interferon-alpha, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma

Urology

Volumn 66, Issue 3, 2005, Pages 518-522

  Sung, Kyu Hong ^a   Kwak, Cheol ^a   Lee, Sang Eun ^a  

^a Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; FLUOROURACIL; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2;

ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; KIDNEY CARCINOMA; MALE; MORALITY; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEPHRECTOMY; PATHOLOGY; PERFORMANCE; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SKIN MANIFESTATION; STATISTICAL SIGNIFICANCE; TUMOR VOLUME; VOMITING; WORLD HEALTH ORGANIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEPHRECTOMY; RETROSPECTIVE STUDIES;

EID: 24144431673     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2005.04.014     Document Type: Article

References (14)

1. R.A. Rabinovitch, M.J. Zelefsky, J.J. Gaynor Patterns of failure following surgical resection of renal cell carcinoma implications for adjuvant local and systemic therapy J Clin Oncol 12 1994 206 212
2. D.A. Levy, J.W. Slaton, D.A. Swanson Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma J Urol 159 1998 1163 1167
3. P. Hermanek, K.M. Schrott Evaluation of the new tumor, nodes, and metastases classification of renal cell carcinoma J Urol 144 1990 238 242
4. R. Finney The value of radiotherapy in the treatment of hypernephroma-a clinical trial Br J Urol 45 1973 258 269
5. M. Kjaer, P.L. Frederiksen, S.A. Engelholm Postoperative radiotherapy in stage II and III renal adenocarcinoma a randomized trial by the Copenhagen Renal Cancer Study Group Int J Radiat Oncol Biol Physiol 13 1987 665 672
6. R.J. Motzer, P. Russo Systemic therapy for renal cell carcinoma J Urol 163 2000 408 417
7. J.I. Clark, M.B. Atkins, W.J. Urba Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma a Cytokine Working Group randomized trial J Clin Oncol 21 2003 3133 3140
8. J.A. Ellerhorst, A. Sella, R.J. Amato Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma Cancer 80 1997 2128 2132
9. J. Atzpodien, H. Kirchner, H.J. Illiger IL-2 in combination with IFN-α and FU versus tamoxifen in metastatic renal cell carcinoma long-term results of a controlled randomized clinical trial Br J Cancer 85 2001 1130 1136
10. G. Pizzaocaro, L. Piva, M. Colavita Interferon adjuvant to radical nephrectomy in Robson stage II and III renal cell carcinoma a multicentric randomized study J Clin Oncol 19 2001 425 431
11. E.J. Lopez Hanninen, H. Kirchner, J. Atzpodien Interleukin-2 based home therapy of metastatic renal cell carcinoma risks and benefits in 215 consecutive single institution patients J Urol 155 1996 19 25
12. M.F. O'Brien, D. Rea, E. Rogers Interleukin-2, interferon-α and 5-fluorouracil immunotherapy for metastatic renal cell carcinoma the all Ireland experience Eur Urol 45 2004 613 619
13. J. Atzpodien, H. Kirchner, U. Jonas Interleukin-2 and interferon alfa-2a based immunochemotherapy in advanced renal cell carcinoma a prospective randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) J Clin Oncol 22 2004 1188 1194
14. P. Padrik Prognostic factors of immunotherapy in metastatic renal cell carcinoma Med Oncol 20 2003 325 334